Title: The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A

Authors:

Sophie Dedieu (sophiededieu@gmail.com)
Xavier Canron (x.canron@hs.u-bordeaux1.fr)
Hamid Rezvani (hrRezvani@yahoo.com)
Marion Bouchecareilh (marionx2@hotmail.com)
Frederic Mazurier (frederic.mazurier@pmtg.u-bordeaux2.fr)
Roberta Sinisi (Roberta.Sinisi@polimi.it)
Matteo Zanda (matteo.zanda@polimi.it)
Michel Moenner (m.moenner@angio.u-bordeaux1.fr)
Andreas Bikfalvi (a.bikfalvi@angio.u-bordeaux1.fr)
Sophie North (s.north@angio.u-bordeaux1.fr)

Version: 2 Date: 9 February 2010

Author's response to reviews:

First submitted to BMC Cancer in July, this manuscript has been reviewed and the revised according to the comment of the reviewers. Revised version was addressed in October to BMC Cancer and virtually accepted. The editorial board offered us to upgrade this manuscript to BMC Medicine in January without any modification. Thus nothing was modified since last October, it is the revised version as it was sent to BMC Cancer in October.